Marina Cuchel

List of Publications by Year
in descending order

54	6,605	236612 25	168136 53
papers	citations	h-index	g-index

55	55	55	7505
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. New England Journal of Medicine, 2011, 364, 127-135.	13.9	1,686
2	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. European Heart Journal, 2014, 35, 2146-2157.	1.0	835
3	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. European Heart Journal, 2015, 36, 2425-2437.	1.0	644
4	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	6.3	624
5	Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science, 2016, 351, 1166-1171.	6.0	438
6	Clinical Genetic Testing for FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2018, 72, 662-680.	1.2	387
7	The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 796-801.	1.1	348
8	ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2017, 377, 296-297.	13.9	258
9	Functional Analysis and Transcriptomic Profiling of iPSC-Derived Macrophages and Their Application in Modeling Mendelian Disease. Circulation Research, 2015, 117, 17-28.	2.0	120
10	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	5.5	114
11	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
12	A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nature Medicine, 2017, 23, 1086-1094.	15.2	88
13	High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1515-1519.	1.1	83
14	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2020, 14, 398-413.	0.6	70
15	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	6.3	69
16	Microsomal Triglyceride Transfer Protein Transfers and Determines Plasma Concentrations of Ceramide and Sphingomyelin but Not Glycosylceramide. Journal of Biological Chemistry, 2015, 290, 25863-25875.	1.6	68
17	Reduced Î²-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. Diabetes, 2017, 66, 134-144.	0.3	62
18	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemiaâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1753-1759.	1.1	60

#	Article	IF	Citations
19	Microsomal transfer protein inhibition in humans. Current Opinion in Lipidology, 2013, 24, 246-250.	1.2	47
20	Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2016, 18, 22.	2.0	39
21	Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress. Cell Reports, 2017, 19, 1456-1466.	2.9	36
22	The frequency of the cholesteryl ester transfer protein-TaqI B2 allele is lower in African Americans than in Caucasians. Atherosclerosis, 2002, 163, 169-174.	0.4	34
23	Loss-of-Function Mutations inABCA1and Enhanced Î²-Cell Secretory Capacity in Young Adults. Diabetes, 2015, 64, 193-199.	0.3	32
24	Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia. Orphanet Journal of Rare Diseases, 2018, 13, 96.	1.2	31
25	Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atherosclerosis Supplements, 2014, 15, 33-45.	1.2	27
26	Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2015, 9, 107-112.	0.6	24
27	ATP-Binding Cassette Transporter A1 Deficiency in Human Induced Pluripotent Stem Cell-Derived Hepatocytes Abrogates HDL Biogenesis and Enhances Triglyceride Secretion. EBioMedicine, 2017, 18, 139-145.	2.7	23
28	A novel approach to measuring macrophage-specific reverse cholesterol transport in vivo in humans. Journal of Lipid Research, 2017, 58, 752-762.	2.0	22
29	ABCA1 and Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1551-1553.	1.1	21
30	JCL roundtable: High-density lipoprotein function and reverse cholesterol transport. Journal of Clinical Lipidology, 2018, 12, 1086-1094.	0.6	20
31	ATP binding cassette family A protein 1 determines hexosylceramide and sphingomyelin levels in human and mouse plasma. Journal of Lipid Research, 2018, 59, 2084-2097.	2.0	16
32	Reconstituted highâ€density lipoprotein can elevate plasma alanine aminotransferase by transient depletion of hepatic cholesterol: role of the phospholipid component. Journal of Applied Toxicology, 2016, 36, 1038-1047.	1.4	15
33	Human serum preÎ²1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases. Nutrition and Metabolism, 2016, 13, 36.	1.3	14
34	Hypoglycemia and Islet Dysfunction Following Oral Glucose Tolerance Testing in Pancreatic-Insufficient Cystic Fibrosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3179-3189.	1.8	13
35	A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model. American Journal of Preventive Cardiology, 2021, 6, 100170.	1.3	12
36	Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics. Clinical Lipidology, 2013, 8, 635-648.	0.4	11

#	Article	IF	Citations
37	A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production. Atherosclerosis, 2014, 235, 470-476.	0.4	11
38	A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. Genetics in Medicine, 2021, 23, 1697-1704.	1.1	11
39	Advancements in the Treatment of Homozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1125-1135.	0.9	11
40	Is Low-Density Lipoprotein Cholesterol the Key to Interpret the Role of Lecithin:Cholesterol Acyltransferase in Atherosclerosis?. Circulation, 2018, 138, 1008-1011.	1.6	10
41	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. Journal of Clinical Lipidology, 2017, 11, 1192-1200.e3.	0.6	9
42	A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency. Journal of Lipid Research, 2022, 63, 100169.	2.0	8
43	Reconstituted High-Density Lipoprotein Therapies. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1800-1802.	1.1	7
44	Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007641.	0.9	7
45	From supravalvular to valvular aortic stenosis: are statins contributing to the phenotypic shift in homozygous familial hypercholesterolaemia?. European Heart Journal, 2022, 43, 3240-3242.	1.0	7
46	Different Î²â€cell secretory phenotype in nonâ€obese compared to obese early type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2020, 36, e3295.	1.7	5
47	HDL and reverse cholesterol transport in humans and animals: Lessons from pre-clinical models and clinical studies. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159065.	1.2	5
48	Familial hypercholesterolaemia: too many lost opportunities. Lancet, The, 2021, 398, 1667-1668.	6.3	4
49	Response to Comment on Rickels et al. Loss-of-Function Mutations inABCA1and Enhanced Î²-Cell Secretory Capacity in Young Adults. Diabetes 2015;64:193â€“199. Diabetes, 2015, 64, e27-e27.	0.3	3
50	Assessing HDL Metabolism in Subjects with Elevated Levels of HDL Cholesterol and Coronary Artery Disease. Molecules, 2021, 26, 6862.	1.7	3
51	Controversial Role of Lecithin:Cholesterol Acyltransferase in the Development of Atherosclerosis: New Insights From an LCAT Activator. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 377-379.	1.1	2
52	Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia: A Quality Improvement Study. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007641.	0.9	1
53	Recognition, diagnosis and treatment of homozygous familial hypercholesterolemia. Expert Opinion on Orphan Drugs, 2017, 5, 933-943.	0.5	0
54	Case report: 68 yo Chinese-American woman with high HDL-C and ischemic stroke attributed to intracranial atherosclerotic stenosis. Journal of Clinical Lipidology, 2021, 15, 248-254.	0.6	0